SG11201810769QA - Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases - Google Patents

Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Info

Publication number
SG11201810769QA
SG11201810769QA SG11201810769QA SG11201810769QA SG11201810769QA SG 11201810769Q A SG11201810769Q A SG 11201810769QA SG 11201810769Q A SG11201810769Q A SG 11201810769QA SG 11201810769Q A SG11201810769Q A SG 11201810769QA SG 11201810769Q A SG11201810769Q A SG 11201810769QA
Authority
SG
Singapore
Prior art keywords
prophylaxis
treatment
substituted indazoles
arthritis
autoimmune diseases
Prior art date
Application number
SG11201810769QA
Other languages
English (en)
Inventor
Alexandra Rausch
Stefan Jodl
Jörn Krätzschmar
Ulrich Bothe
Nicole Schmidt
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201810769QA publication Critical patent/SG11201810769QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201810769QA 2016-06-01 2017-05-24 Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases SG11201810769QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172507 2016-06-01
PCT/EP2017/062535 WO2017207386A1 (de) 2016-06-01 2017-05-24 Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen

Publications (1)

Publication Number Publication Date
SG11201810769QA true SG11201810769QA (en) 2018-12-28

Family

ID=56097014

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810769QA SG11201810769QA (en) 2016-06-01 2017-05-24 Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
SG10202011653WA SG10202011653WA (en) 2016-06-01 2017-05-24 Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202011653WA SG10202011653WA (en) 2016-06-01 2017-05-24 Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Country Status (22)

Country Link
US (3) US20190125736A1 (uk)
EP (1) EP3463354A1 (uk)
JP (1) JP7099966B2 (uk)
KR (1) KR102460362B1 (uk)
CN (1) CN109152771B (uk)
AU (1) AU2017273771B2 (uk)
BR (1) BR112018074919A2 (uk)
CA (1) CA3025826A1 (uk)
CL (1) CL2018003409A1 (uk)
EA (1) EA201892790A1 (uk)
HK (1) HK1258914A1 (uk)
IL (1) IL263230B (uk)
JO (1) JOP20170136B1 (uk)
MA (1) MA45089A (uk)
MX (1) MX2018014897A (uk)
NZ (1) NZ748907A (uk)
PH (1) PH12018502531A1 (uk)
SG (2) SG11201810769QA (uk)
TN (1) TN2018000409A1 (uk)
TW (1) TWI784954B (uk)
UA (1) UA123916C2 (uk)
WO (1) WO2017207386A1 (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN109153665B (zh) 2016-03-03 2021-10-15 拜耳医药股份有限公司 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
BR112018072242A2 (pt) 2016-04-29 2019-04-09 Bayer Pharma Aktiengesellschaft forma polimórfica de n-{6-(2-hidróxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridina-2-carboxamida
CU24593B1 (es) 2016-04-29 2022-05-11 Bayer Pharma AG Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
RU2743170C2 (ru) * 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
WO2020036830A1 (en) * 2018-08-13 2020-02-20 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
JP2022541265A (ja) * 2019-07-18 2022-09-22 ブリストル-マイヤーズ スクイブ カンパニー IRAK4阻害剤として有用なピラゾロ[3,4-d]ピロロ[1,2-b]ピリダジニル化合物
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
CN113402499B (zh) * 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
WO2023152349A1 (en) 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
WO2023227703A1 (en) 2022-05-26 2023-11-30 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
WO2024108010A1 (en) * 2022-11-17 2024-05-23 Bayer Animal Health Gmbh Methods and compositions for control of pain and inflammation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2591332A1 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2012061926A1 (en) 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
ES2591129T3 (es) 2012-05-21 2016-11-25 Bayer Pharma Aktiengesellschaft Tienopirimidinas
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
BR112016015983A2 (pt) * 2014-01-10 2017-08-08 Aurigene Discovery Tech Ltd Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
MX2016017147A (es) * 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
CN109153665B (zh) 2016-03-03 2021-10-15 拜耳医药股份有限公司 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CU24593B1 (es) 2016-04-29 2022-05-11 Bayer Pharma AG Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
BR112018072242A2 (pt) 2016-04-29 2019-04-09 Bayer Pharma Aktiengesellschaft forma polimórfica de n-{6-(2-hidróxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridina-2-carboxamida
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных

Also Published As

Publication number Publication date
WO2017207386A1 (de) 2017-12-07
US20190125736A1 (en) 2019-05-02
CN109152771A (zh) 2019-01-04
CL2018003409A1 (es) 2019-03-22
US20210085664A1 (en) 2021-03-25
IL263230A (en) 2019-01-31
US11992481B2 (en) 2024-05-28
MX2018014897A (es) 2019-04-24
TWI784954B (zh) 2022-12-01
BR112018074919A2 (pt) 2020-11-03
TN2018000409A1 (en) 2020-06-15
EP3463354A1 (de) 2019-04-10
JP2019517495A (ja) 2019-06-24
AU2017273771B2 (en) 2022-09-29
NZ748907A (en) 2023-04-28
SG10202011653WA (en) 2020-12-30
US20220249456A1 (en) 2022-08-11
CA3025826A1 (en) 2017-12-07
EA201892790A1 (ru) 2019-06-28
MA45089A (fr) 2019-04-10
CN109152771B (zh) 2022-07-19
KR102460362B1 (ko) 2022-10-28
JOP20170136B1 (ar) 2023-09-17
IL263230B (en) 2021-09-30
JP7099966B2 (ja) 2022-07-12
UA123916C2 (uk) 2021-06-23
AU2017273771A1 (en) 2018-12-20
TW201742862A (zh) 2017-12-16
HK1258914A1 (zh) 2019-11-22
PH12018502531A1 (en) 2019-10-21
KR20190015251A (ko) 2019-02-13

Similar Documents

Publication Publication Date Title
SG11201810769QA (en) Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
TN2017000226A1 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
TN2015000370A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
MX2018006223A (es) Moduladores de ror-gamma.
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2020001361A (es) Compuestos nuevos como moduladores de ror gamma.
TN2017000181A1 (en) Pharmaceutical products and stable liquid compositions of il-17 antibodies
MX367335B (es) Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias.
MY171226A (en) Antibodies that bind il-23
PH12016501105A1 (en) Bicyclic heteroaryl indole analogues useful as ror gamma modulators
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
PH12017500403A1 (en) Anti-il-25 antibodies and uses thereof
MX2019002672A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atopica.
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
MX2020002852A (es) Tratamiento mejorado de dermatitis atopica con tradipitant.
WO2016199170A3 (en) Paliperidone palmitate particles and compositions thereof
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
MX2022015234A (es) Isoxazolidinas como inhibidores de ripk1 y uso de las mismas.
MY187276A (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
TN2019000083A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX371538B (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
MY188028A (en) Sialylated glycoprotein compositions and uses thereof